section name header

Pronunciation

sul-fa-SAL-a-zeen

Classifications

Therapeutic Classification: antirheumatics (DMARD), gastrointestinal anti-inflammatories

Indications

REMS


Action

  • Locally acting anti-inflammatory action in the colon, where activity is probably a result of inhibition of prostaglandin synthesis.
Therapeutic effects:
  • Reduction in the symptoms of ulcerative colitis or rheumatoid arthritis.

Pharmacokinetics

Absorption: 10–15% absorbed after oral administration.

Distribution: Widely distributed; crosses the placenta and enters breast milk.

Protein Binding: 99%.

Metabolism/Excretion: Split by intestinal bacteria into sulfapyridine and 5-aminosalicylic acid. Some absorbed sulfasalazine is excreted by bile back into intestines; 15% excreted unchanged by the kidneys. Sulfapyridine also excreted mostly by the kidneys.

Half-Life: 6 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
PO1 hr1.5–6 hr6–12 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Ulcerative Colitis

Rheumatoid Arthritis

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Azulfidine, Azulfidine EN-tabs

Canadian Brand Names

Salazopyrin